Crispr Therapeutics: Assessing The Recent Capital Financing – Seeking Alpha
Seeking Alpha |
Crispr Therapeutics: Assessing The Recent Capital Financing
Seeking Alpha On Jan 05, 2018, the share price of Crispr Therapeutics (NASDAQ:CRSP), a bioscience focusing on gene-editing and CAR-T to treat serious conditions such as cancers and genetic diseases, continued its rally. The stock added another $2.90 (over 12 … |
